Supernus Pharmaceuticals Debt Issuance/Retirement Net - Total 2011-2024 | SUPN
Supernus Pharmaceuticals debt issuance/retirement net - total from 2011 to 2024. Debt issuance/retirement net - total can be defined as the total amount of short term and long term borrowings repaid and issued.
Supernus Pharmaceuticals Annual Debt Issuance/Retirement Net - Total
(Millions of US $) |
| 2024 |
$N/A |
| 2023 |
$-403 |
| 2022 |
$N/A |
| 2021 |
$-138 |
| 2020 |
$N/A |
| 2019 |
$N/A |
| 2018 |
$403 |
| 2017 |
$N/A |
| 2016 |
$N/A |
| 2015 |
$N/A |
| 2014 |
$N/A |
| 2013 |
$66 |
| 2012 |
$-7 |
| 2011 |
$30 |
| 2010 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.805B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
